The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Current therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this setting. Vimentin plays a role in carcinogenesis through the activation of the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Bronte, Giuseppe, Puccetti, Maurizio, Petracci, Elisabetta, Landi, Lorenza, Cravero, Paola, Scodes, Simona, Ulivi, Paola, Ravaioli, Sara, Tumedei, Maria Maddalena, Burgio, Marco Angelo, Cappuzzo, Federico, Delmonte, Angelo, Crinò, Lucio, Bravaccini, Sara
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130554/
https://ncbi.nlm.nih.gov/pubmed/34017688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.669839
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars